Navigation Links
Keryx Biopharmaceuticals to Present at the Cowen and Company 28th Annual Health Care Conference
Date:3/13/2008

differentiation and cell survival. KRX-0401, which is currently in Phase 2 clinical development for multiple tumor types, is expected to move into a Phase 3 clinical program in 2008. The Company also has an active in-licensing and acquisition program designed to identify and acquire additional drug candidates. Keryx is headquartered in New York City.

KERYX CONTACT:

Lauren Fischer

Director - Investor Relations

Keryx Biopharmaceuticals, Inc.

Tel: 212.531.5965

E-mail: lfischer@keryx.com


'/>"/>
SOURCE Keryx Biopharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Keryx Biopharmaceuticals Announces that SUN-MICRO Phase 3 Clinical Trial Fails to Meet Primary Efficacy Endpoint
2. Keryx Biopharmaceuticals, Inc. Announces Fourth Quarter and Year-End 2007 Financial Results
3. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Fourth Quarter and Year-End 2007 Financial Results on Monday, February 25, at 8:30 A.M. EST
4. Keryx Biopharmaceuticals Announces Additions to Management Team
5. Keryx Biopharmaceuticals Announces Upcoming Corporate Presentations
6. Keryx Biopharmaceuticals, Inc. Announces Third Quarter 2007 Financial Results
7. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Third Quarter 2007 Financial Results on Thursday, October 25, at 8:30 A.M. EDT
8. Keryx Biopharmaceuticals, Inc. Enters into Licensing Agreement with Japan Tobacco and Torii Pharmaceutical for Development and Commercialization of Hyperphosphatemia Drug in Japan
9. Keryx Biopharmaceuticals, Inc. Announces Conference Call to Discuss Strategic Alliance
10. Keryx Biopharmaceuticals, Inc. Announces Appointment of Michael P. Tarnok to Board of Directors
11. Keryx Biopharmaceuticals to Present at Bank of America Investment Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2013)... 2013 Custom Learning Designs, Inc.(CLD) ... solution using Tin Can API combined with its ... is a leading developer of training content and ... worldwide. , Tin Can API is a ... and trainers more accurately measure the Return on ...
(Date:5/21/2013)... May 21, 2013 The congress ... Transplant Association) is the biggest congress in ... Nearly 10,000 participants are in Istanbul ... research findings. New pioneering studies have been presented: ... PYROPHOSPHATE (SFP) ADMINISTERED VIA HEMODIALYSATE REDUCES ESA USE" ...
(Date:5/21/2013)... York , May 21, 2013 ... Transparency Market Research ( http://www.transparencymarketresearch.com ) "Biochip Products and ... IVD Tests) - U.S. Industry Analysis, Size, Share, Growth, Trends and ... billion in 2011 and is expected to grow at ... reach an estimated value of USD 4.7 billion in ...
(Date:5/21/2013)... May 21, 2013  MacroGenics, Inc. today announced ... margetuximab (MGAH22), an Fc-modified chimeric monoclonal antibody (MAb), ... HER2 oncoprotein," will be presented at the 2013 ... Oncology during the Developmental Therapeutics - Immunotherapy Oral ... – 4:30 PM.  The presentation will describe the ...
Breaking Biology Technology:CLD Integrates Tin CAN API with its eLearning Solutions and Launches its Excelerometer Tracking Statement Dashboard 2CLD Integrates Tin CAN API with its eLearning Solutions and Launches its Excelerometer Tracking Statement Dashboard 3ERA-EDTA CONGRESS 2013: Late Breaking Clinical Trials 2ERA-EDTA CONGRESS 2013: Late Breaking Clinical Trials 3The U.S. Biochip Products and Services Market is Expected to Reach USD 4.7 Billion in 2018: Transparency Market Research 2The U.S. Biochip Products and Services Market is Expected to Reach USD 4.7 Billion in 2018: Transparency Market Research 3The U.S. Biochip Products and Services Market is Expected to Reach USD 4.7 Billion in 2018: Transparency Market Research 4The U.S. Biochip Products and Services Market is Expected to Reach USD 4.7 Billion in 2018: Transparency Market Research 5MacroGenics Announces Margetuximab (MGAH22) Phase 1 Data Presentation at ASCO; Initiates Phase 2 Clinical Study to Evaluate Activity of Margetuximab in Patients with Metastatic Breast Cancer 2MacroGenics Announces Margetuximab (MGAH22) Phase 1 Data Presentation at ASCO; Initiates Phase 2 Clinical Study to Evaluate Activity of Margetuximab in Patients with Metastatic Breast Cancer 3
... Jan. 11 /PRNewswire-FirstCall/ - Vasogen Inc.,(NASDAQ: VSGN ; ... and,commercial development of technologies targeting the chronic inflammation,underlying ... at 4:10 p.m. on Wednesday, January 16, 2008. ... Time, during which management will,provide a Company update ...
... by Mark Walton, Ph.D., President, ViaGen, January 11, ... the,European Food Safety Authority,s strong endorsement of the safety ... U.S. Food and Drug,Administration to release its final risk ... voluntary moratorium. The international,scientific consensus is clear: food from ...
... Biodesign Institute have developed the worlds first gene detection ... results, appearing in the January 11 issue of the ... technology and may also revolutionize the way in which ... We are starting with the most well-known structure in ...
Cached Biology Technology:Vasogen to Conduct Year-end 2007 Conference Call 2Vasogen to Conduct Year-end 2007 Conference Call 3Vasogen to Conduct Year-end 2007 Conference Call 4Statement on the Release of the European Food Safety Assessment on the Safety of Food Derived From Clones and Their Offspring in the Food Supply 2Nanotechnology innovation may revolutionize gene detection in a single cell 2Nanotechnology innovation may revolutionize gene detection in a single cell 3
(Date:5/21/2013)... shape is an uphill battle? Try staying fit in ... withers muscle and bone. , That,s the challenge a ... a new three-year, $1.2 million grant from NASA. Their ... multiyear exploratory missions. , "You could give astronauts the ... get them to stick to it, it isn,t going ...
(Date:5/21/2013)... of insulin action in cells in precise detail like ... what goes wrong in diabetes. , The breakthrough ... from Sydney,s Garvan Institute of Medical Research, is now ... journal Cell Metabolism . , First discovered in ... in the body because it helps us lower blood ...
(Date:5/20/2013)... University of Minnesota Medical School researchers from the ... the University,s Brain Tumor Program, have developed a new ... that allow them to discover new genes and gene ... was published this week in the journal Nature ... researchers in the lab of David Largaespada, Ph.D., professor ...
Breaking Biology News(10 mins):Fueling fitness on the final frontier 2Insight into the dazzling impact of insulin in cells 2Insight into the dazzling impact of insulin in cells 3U of M researchers develop model for better testing, targeting of MPNST 2
... The history of evolution is periodically marked by explosions ... wide range of shapes and sizes. With a new ... record, researchers have discovered that these diversifications proceeded head-first. ... that diversified around the time of two separate extinction ...
... to help prevent or reduce severe wildfire will release more ... fire prevention, a new study concludes. There may be ... forest structure or health, wildlife enhancement or public safety ... say. In research just published in Frontiers in ...
... LIFE the Faculty of Life Sciences at the University ... growth pattern than non-breastfed children. Breastfeeding lowers the levels of ... means that growth is slightly slower. This is believed to ... The PhD project is part of SKOT, a ...
Cached Biology News:'Head-first' diversity shown to drive vertebrate evolution 2'Head-first' diversity shown to drive vertebrate evolution 3Forest health versus global warming: Fuel reduction likely to increase carbon emissions 2Breastfeeding promotes healthy growth 2
MAb to Transferrin Dry Ice: No Preservative: NaN3 Availability When Not in Inventory: 14-21 Business Days...
Anti-ADAMTS-4, disintegrin-like domain Immunogen: Synthetic peptide - KLH conjugated Available Date: 38569...
WD-repeat protein 4...
ANXA11 Immunogen: ANXA11 (NP_001148, 406 a.a. ~ 506 a.a) partial recombinant protein with GST tag. Storage: -20 C, Avoid Freeze/Thaw Cycles *Available for distribution in the US only...
Biology Products: